Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: Results of NCIC CTG MA.14

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3605-3610

  Lipton, Allan ^a,b,c,d,e   Chapman, Judy Anne W ^a,b,c,d,e   Demers, Laurence ^a,b,c,d,e   Shepherd, Lois E ^a,b,c,d,e   Han, Lei ^a,b,c,d,e   Wilson, Carolyn F ^a,b,c,d,e   Pritchard, Kathleen I ^a,b,c,d,e   Leitzel, Kim E ^a,b,c,d,e   Ali, Suhail M ^a,b,c,d,e   Pollak, Michael ^a,b,c,d,e  

^a PENN STATE CANCER INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; OCTREOTIDE; TAMOXIFEN; TELOPEPTIDE;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NATIONAL HEALTH ORGANIZATION; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TOXICITY; TUMOR VOLUME;

BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; COLLAGEN TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE;

EID: 80053056356     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5069     Document Type: Article

References (19)

1. Coleman RE: Bisphosphonates: Clinical experience. Oncologist 9:14-27, 2004 (suppl 4)
2. Mundy GR: Metastases to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2002
3. Demers LM, Costa L, Lipton A: Biochemical markers and skeletal metastases. Clin Orthop Relat Res 415:S138-S147, 2003 (suppl) (Pubitemid 37323331)
4. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1:571-573, 1889
5. Chung LW, Baseman A, Assikis V, et al: Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 173:10-20, 2005 (Pubitemid 39627663)
6. Pollak MN, Chapman JW, Pritchard KI, et al: NCIC-CTG MA14 trial: Tamoxifen(tam) vs. tam +octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. J Clin Oncol 26:14s, 2008 (suppl; abstr 532)
7. Piura E, Chapman JW, Lipton A, et al: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 534)
8. Rosenquist C, Fledelius C, Christgau S, et al: Serum CrossLaps One Step ELISA: First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281-2289, 1998 (Pubitemid 28511750)
9. Christgau S, Rosenquist C, Alexandersen P, et al: Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44: 2290-2300, 1998 (Pubitemid 28511751)
10. Box GEP, Cox DR: Analysis of transformations. J Roy Stat Soc Ser Bull 26:211-252, 1964
11. Lawless JF: Statistical Models and Methods for Lifetime Data (ed 2). Hoboken, NJ, John Wiley & Sons, 2003, pp 98-139
12. Burnell M, Levine MN, Chapman JW, et al: Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28:77-82, 2010
13. Dallas SL, Rosser JL, Mundy GR, et al: Proteolysis of latent transforming growth factor-beta (TGF-beta)- binding protein-1 by osteoclasts: A cellular mechanism for release of TGF-beta from matrix. J Biol Chem 277:21352-21360, 2002 (Pubitemid 34952275)
14. Kang Y, Siegel RM, Shu W, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549, 2003 (Pubitemid 36808649)
15. Kang Y, He W, Tulley S, et al: Breast cancer bone metastasis mediated by the SMAD tumor suppressor pathway. Proc Natl Acad Sci U S A 102:13909-13914, 2005 (Pubitemid 41377677)
16. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
17. Eidtmann H, Bundred N, De Boer R, et al: The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. Cancer Res 69:74S, 2009 (suppl 2)
18. Coleman RE, Thorpe HC, Cameron D, et al: Adjuvant treatment with zoledronic acid in stage II/III breast cancer: The AZURE trial (BIG 01/04). Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S4-5)
19. Solomayer EF, Gebauer G, Himle P, et al: Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Cancer Res 69:170s-171s, 2009 (suppl 2; abstr 2048)